A new ERBB2 (HER2) targeting TKI is approved for NSCLC. We review the characteristics of the drug and summarize the current landscape in treating HER-mutated advanced NSCLC.

This week's episode discusses the first-in-class agent, dordaviprone and a randomized control trial that demonstrated an oncology pharmacists led to decreased rates of adverse drug reactions (ADRs) in a Hem/Onc clinic.

Dordaviprone data: https://doi.org/10.1200/jco.23.01134

Alabassi AK, et al. Role of a designated pharmacist in reducing adverse drug reaction rates and preventing potential medication errors in hematology-oncology: a randomized controlled trial. JCO Oncology Practice: https://doi.org/10.1200/OP-25-00158

More isn't always better. Our Landkmarks of OncoPharm series covers lessons learned from the ProMACE-CytaBOM regimen for NHL.

ProMACE-CytaBOM: https://www.annalsofoncology.org/article/S0923-7534(20)31592-1/pdf

RCT vs. CHOP (& others): https://www.nejm.org/doi/full/10.1056/NEJM199304083281404

A brief overview of testicular cancer

A few supportive care updates:

1. Skin prophylaxis to prevent severe dermatologic toxicity with Nivo/Ipi.

Note* published in JCO Oncology Practice (NOT JAMA Oncol as stated in the episode

Link: https://doi.org/10.1200/OP-25-00100

2. Stampede-Metformin and how metformin has some beneficial effects in prostate cancer patients who don't have diabetes

Link: https://doi.org/10.1016/S1470-2045(25)00231-1

Two new drug approvals to talk about (after I misplaced my notes!)

Antiandrogen withdrawal is an historically well described phenomenon where prostate cancer patients experience PSA responses AFTER stopping their anti-androgen. But does this happen with today's 2nd generation antiandrogens?

A plethora of recent updates:

-Pembrolizumab (perioperative) in head & neck cancer (Keynote-689)

-Prostate cancer updates on cabozantinib/atezolizumab (yes, really) and talazoparib

-Pirtobrutinib improves PFS in CLL

-Zanubrutinib has a new dosage form on the way

-Another mitomycin product approved with "reverse thermal properties"

-A new regimen for FL of tafasitamab/rituximab/lenalidomide

-A comparison of the new ROS1-inhibitor, taltrectenib, compared to other 1st-line treatment options

A recap of notable updates from ASCO 2025

1. Destiny-Breast09

2. BREAKWATER

3. ATOMIC

4. Delphi-304

5. CM 816 OS update

6. C-POST

7. Matterhorn

Our Landmarks of OncoPharm series returns to discuss the CLEOPATRA study, which established docetaxel, trastuzumab, pertuzumab (THP) as a standard first-line regimen for metastatic HER2-amplified breast cancer.